ABL1 and non-small cell lung carcinoma: To determine the activity of imatinib against NSCLC cells harboring an ABL1 mutation in vivo, we established murine NSCLC xenograft models using the H1915 cell line, carrying R351W homozygous mutation in ABL1, and the H650 cell line, expressing wild‐type ABL1 as a control model.